News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Artificial Pancreas Race Intensifies Between These 3 Medtech Firms



11/21/2016 8:14:20 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Expected to start late this year, the International Diabetes Closed-Loop Trial (IDCLT) will combine technologies from three companies that are looking to make major strides in type 1 diabetes therapy via commercialization of a true artificial pancreas: Tandem Diabetes Care, Dexcom, and TypeZero Technologies.

The trial—sponsored by the University of Virginia and funded by NIH—will include 240 people between the ages of 14 and 75 who have type 1 diabetes.

IDCLT is set up as “a pivotal trial of a closed-loop control-to-range system and includes seven institutions in the United States and three in Europe led by the University of Virginia,” Boris Kovatchev, PhD, director of the Center for Diabetes Technology at the University of Virginia and principal investigator of IDCLT, said in a statement.

Read at Qmed


comments powered by Disqus
Qmed
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES